NomosLogic

Privacy Policy

Data Use, Protection, and Patient Rights

Effective Date: January 1, 2026 · Version 1.0

NomosLogic is a privacy-first precision medicine platform. This policy exists to make our patient-first and privacy-protective operating model explicit, durable, and public.

1. Data Privacy & Sovereign Ownership

You remain the sole owner of your genomic, laboratory, and related health data. NomosLogic acts as a custodian and processing platform with no ownership claim over your personal biological information.

NomosLogic is not a data broker and does not operate a data resale business. We do not sell, lease, rent, or otherwise commercialize identifiable personal health data through data marketplace, advertising, or resale channels.

Research conducted through NomosLogic is intended to occur through controlled, privacy-preserving study execution inside our systems rather than through transfer or sale of individualized records.

Upon deletion, identifiable genetic data is purged within thirty days per the Delaware Personal Data Privacy Act, subject to legal, regulatory, and audit-retention obligations.

2. HIPAA & Security Standards

All data is encrypted with AES-256 at rest and TLS 1.2+ in transit. Access is restricted to authorized workflows and operational personnel with role-based controls, logging, and audit traceability.

NomosLogic voluntarily adheres to HIPAA Security and Privacy Rules for Protected Health Information.

Where data is used to improve system quality, safety, or performance, it is handled under controlled internal processes, with identifying context minimized or removed where appropriate to the use case.

3. Clinical Boundary and Intended Use

NomosLogic is molecular medicine infrastructure. It provides deterministic genomic interpretation, evidence-anchored analysis, and structured decision-support output intended to improve the clarity, traceability, and usability of molecular findings. It is not a substitute for direct clinical evaluation, diagnosis, or treatment by a licensed healthcare professional, and use of the platform does not create a physician-patient relationship.

Platform findings should be interpreted in the context of the full clinical picture. Decisions involving medication changes, treatment selection, or other medical management should be made with a qualified licensed clinician.

4. Data Usage & Ingestion

Uploading lab PDFs or connecting EHR authorizes Biomarker Analysis Module parsing. Wearable connections and other optional integrations are revocable through settings or support workflows where applicable.

Data is ingested to provide precision care, decision support, report generation, coordination with authorized providers, and controlled research execution consistent with user permissions, institutional controls, and applicable law.

NomosLogic does not use your health data to build advertising profiles, sell audience segments, or support third-party ad targeting.

5. Limitation of Liability & Indemnity

NomosLogic is not liable for indirect, incidental, or consequential damages arising from platform use. Users indemnify the company from claims arising from agreement breach or misuse.

6. Mandatory Arbitration & Class Action Waiver

Disputes shall be resolved through binding arbitration in Salt Lake City, Utah or Wilmington, Delaware. Users waive the right to participate in class-action lawsuits or class-wide arbitration.

7. AI and Automated Processing Disclosure

The platform may include automated computational and software-assisted features used to organize, prioritize, summarize, or present information. Such features are supportive in nature and are not, by themselves, medical advice, diagnosis, or treatment recommendations. Users should not rely solely on automated output when making healthcare decisions.

8. Governing Law

This agreement is governed by the laws of the State of Delaware without regard to conflict of law principles.